(Reuters) - Hyperion Therapeutics Inc said it would stop development of a diabetes drug following discovery of unlawful conduct by some employees of a recently acquired subsidiary, sending its shares down 25 percent premarket. The company said some employees of Andromeda Biotech Ltd, which Hyperion acquired in June, engaged in serious misconduct that involved receiving unblinded data from the trial, DIA-AID 1, and manipulating it to obtain a favorable result. Hyperion said additional evidence indicates that the employees of Andromeda, which is based in Israel, continued sharing and examining unblinded data from an ongoing DIA-AID 2 trial. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment